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Eph receptor tyrosine kinases and their ligands (ephrins)
have a pivotal role in the homeostasis of many adult organs
and are widely expressed in the kidney. Glomerular diseases
beginning with mesangiolysis can recover, with podocytes
having a critical role in this healing process. We studied here
the role of Eph signaling in glomerular disease recovery
following mesangiolytic Thy1.1 nephritis in rats. EphB4 and
ephrinBs were expressed in healthy glomerular podocytes
and were upregulated during Thy1.1 nephritis, with EphB4
strongly phosphorylated around day 9. Treatment with
NPV-BHG712, an inhibitor of EphB4 phosphorylation, did not
cause glomerular changes in control animals. Nephritic
animals treated with vehicle did not have morphological
evidence of podocyte injury or loss; however, application
of this inhibitor to nephritic rats induced glomerular
microaneurysms, podocyte damage, and loss. Prolonged
NPV-BHG712 treatment resulted in increased albuminuria
and dysregulated mesangial recovery. Additionally,
NPV-BHG712 inhibited capillary repair by intussusceptive
angiogenesis (an alternative to sprouting angiogenesis),
indicating a previously unrecognized role of podocytes in
regulating intussusceptive vessel splitting. Thus, our results
identify EphB4 signaling as a pathway allowing podocytes to
survive transient capillary collapse during glomerular disease.
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Thy1.1 nephritis is one of the most commonly used models
to study the course of immunoglobulin A and other mesan-
gioproliferative nephropathies.1 To date, most of the studies
have focused on mesangial and, to a lesser extent, endothelial
cell recovery following capillary damage,2 whereas data con-
cerning the podocyte response are still scarce. Podocytes are
terminally differentiated epithelial cells with a distinctive
morphology. Their foot processes and the slit membrane are
localized at the basolateral site, while a well-developed cell
body faces the urinary space.3 Proteins located at the basolateral
site have been extensively studied owing to their involvement
in maintaining podocyte attachment to the basement mem-
brane and barrier function against proteinuria.4,5 It is, however,
not unusual for apically expressed proteins to regulate the
function of foot processes and overall podocyte homeo-
stasis.6,7 Therefore, alterations in apical membrane domains
are one of the events leading to podocyte degeneration.8
Unlike endothelial and mesangial cells, podocytes have very
limited capability of self-renewal, making their injury a
critical step in the pathogenesis of nephropathies.9
Recently ephrinB1, a ligand of the EphB family of receptor
tyrosine kinases, has emerged as yet another protein located
at the glomerular slit membrane.10 The specific feature of
these versatile molecules is the possibility of bidirectional
signaling, where not only the Eph receptor (forward signaling)
but also the membrane-bound ephrin ligand (reverse signaling)
can convey an intracellular signal. Eph/ephrins have previously
attracted a lot of attention owing to their crucial involvement
in the development of the vascular and nervous systems.11
Among Eph/ephrins, EphB4 and its ligand ephrinB2 were
first described as critical molecules regulating vascular develop-
ment, where EphB4-expressing venous endothelial cells assem-
ble with ephrinB2-expressing arterial endothelium to form
functional vasculature. As the EphB4/ephrinB2 pair acts in
this setting as reciprocal signaling partners, their loss causes
similar phenotypes in mouse embryos.12 Also, there is
evidence that EphB4/ephrinB2 control bone homeostasis13
as well as vascular biology in the adult organism.14 Eph/ephrins
are also expressed in the adult kidney;15,16 however, their
involvement in glomerular recovery from acute glomerulo-
nephritis has not been addressed.
or ig ina l a r t i c l e http://www.kidney-international.org
& 2012 International Society of Nephrology
Received 9 March 2011; revised 6 December 2011; accepted 13
December 2011; published online 7 March 2012
Correspondence: Uyen Huynh-Do, Department of Nephrology and
Hypertension, and Department of Clinical Research, University of Bern
Medical School, Inselspital, 3010 Bern, Switzerland.
E-mail: uyen.huynh-do@insel.ch
4Present address: Samuel Lunenfeld Research Institute, Mount Sinai
Hospital, Toronto, ON, Canada.
5Present address: Roche AG, Basel, Switzerland.
1212 Kidney International (2012) 81, 1212–1225
EphrinBs
EphrinBs
EphrinBs
Ctrl D5 D9 D14 D21
EphB4
WB: PTyr
IP: EphB4 Ctrl D5 D9 D21
WB: EphB4
Ep
hB
4 
m
RN
A
EphB4
β-Actin
5
4
***
***
*
*
**3
R
el
at
ive
 g
lo
m
er
u
la
r 
ex
pr
es
sio
n
Ctr
l
D5 D9 D1
4
D2
1
2
1
0
Ep
hr
in
Bs
/p
od
oc
in
Ep
hB
4/
po
do
cin
EphB4
Ctrl
Ctrl
pEphrinBs
D9
D9 D9D21
Figure 1 | EphB4 receptor is markedly activated in the glomeruli of nephritic rats. (a) EphB4 receptor and ephrinBs are expressed in
healthy rat glomeruli (original magnification  1000). (b) Western blotting of glomeruli lysates showed that ephrinBs and EphB4 were
upregulated during nephritis (n¼ 4 in control (ctrl), n¼ 5 at day (D) 21 and n¼ 6 at D5, D9, and D14; each n is a glomerular lysate from one
animal). (c) Phosphorylated ephrinBs (pEphrinBs) were detected in the glomeruli at D9 of nephritis, but not in the healthy rats. (d) EphB4
activation was detected at D9 of nephritis. (e–g) EphrinBs colocalized with podocin, a marker of podocyte foot processes, in healthy
and nephritic glomeruli. (h–j) EphB4 staining was shifted towards the urinary space when compared to podocin fluorescence (enlarged
area and arrows). (k) EphB4 mRNA was detected at the periphery of glomerular lobules at D9 of nephritis (arrows). n¼ 4 in d, n¼ 3 in
k; d and k show representative images. IP, immunoprecipitation; PTyr, phosphotyrosine; WB, western blotting. *Po0.05; **Po0.01;
***Po0.001.
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RESULTS
EphB4 receptor is markedly activated in the glomeruli of
nephritic rats
Immunohistochemical analysis demonstrated protein expres-
sion of EphB4 receptor and ephrinBs in healthy rat glomeruli
(Figure 1a). Using the same antibodies, we did not detect
EphB4 in mouse glomeruli (Supplementary Figure S1
online), in accordance with Takahashi et al.17 and suggesting
differences within rodents.
Western blot analysis of glomerular lysates showed a marked
ephrinB upregulation and a milder increase of EphB4 during
nephritis (Figure 1b). Phosphorylated ephrinBs could not be
detected in healthy glomeruli, but were readily observed upon
nephritis induction (Figure 1c). The most striking result,
however, was a strong phosphorylation of EphB4 at day 9 of
nephritis (Figure 1d). EphB4/ephrinBs could be also detected
in the tubular epithelium (Supplementary Figures 1c–f and
2a–d online, respectively).
Colocalization studies detected ephrinBs along with the
podocyte marker podocin in healthy and nephritic glomeruli
(Figure 1e–g). EphB4 showed, however, only weak or no colo-
calization with podocin (Figure 1h–j). The receptor staining was
strongest towards the urinary space (enlarged area and arrows).
As podocin is a marker of foot processes, the EphB4 staining
pattern is consistent with a predominant expression at the apical
part of podocytes. No colocalization was observed between
EphB4 and endothelial (CD31) or mesangial (a smooth muscle
actin (aSMA)) markers (Supplementary Figure S2e–f online).
To confirm podocyte-specific EphB4 expression during
the disease, we performed in situ hybridization to detect
EphB4 mRNA. Although the signal was not very strong, we
could detect EphB4 mRNA at the outer rim of nephritic
glomeruli, consistent with the localization within podocytes
(Figure 1k, arrows).
NPV-BHG712 impairs glomerular recovery from
Thy1.1 nephritis
To delineate the role of podocyte EphB4 during nephritis, we
used NPV-BHG712, a novel and to date the only specific,
in vivo-validated small-molecular-weight inhibitor of EphB4
phosphorylation.18 Pharmacological data of NPV-BHG712 in
rats are shown in Supplementary Figure S3 online.
In preliminary titration experiments, we showed that
50mg/kg b.w. NPV-BHG712 delivered i.p. completely inhibited
EphB4 phosphorylation (Figure 2a and b). We then sought to
exclude the potential off-target actions of NPV-BHG712. As
NPV-BHG712 also inhibits EphB2 and EphA2, we looked for
their glomerular expression. EphB2 was absent in rat glo-
meruli, whereas EphA2 was expressed but unphosphorylated
in both healthy and nephritic glomeruli (Figure 2d and e).
Also, we showed that NPV-BHG712 had no effect on
phosphorylated c-Src or extracellular signal-regulated kinases
in nephritic rats, in sharp contrast to the complete inhibition
of glomerular EphB4 activation (Figure 2c). These results
suggest that the observed biological end points are primarily
due to inhibition of podocyte EphB4 signaling.
We next applied NPV-BHG712 to healthy rats according
to the schedule depicted in Figure 3a. We did not observe any
effects of NPV-BHG712 on podocyte number (Figure 3b)
and the glomerular morphology (Figure 3c–i). NPV-BHG712
did not cause albuminuria, glomerulosclerosis, or micro-
aneurysms (data not shown).
We then induced nephritis by a single i.v. shot of OX7
antibody, and randomly allocated animals to either NPV-
BHG712 or the vehicle group. We chose to apply these
compounds between day 5 and day 9 of glomerulonephritis
(Figure 4a) because glomerular EphB4 phosphorylation was
initiated during this critical time period. Kidney/body weight
ratio and albuminuria were not influenced by NPV-BHG712
(Figure 4b and c), but NPV-BHG712 aggravated the injury to
glomerular capillaries as assessed by the presence of glomeruli
with microaneurysms (Figure 4d) and further increased
glomerular volume (Figure 4e). Interestingly, EphB4 inhibi-
tion reduced the number of glomerular macrophages
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Figure 2 |NPV-BHG712 inhibits EphB4 forward signaling in rat
tissues. (a) The strongest expression and phosphorylation band
of EphB4 were detected in the lung tissue of healthy Wistar rats as
compared with the kidney, liver, and spleen. (b) A single dose
of 50mg/kg b.w. of NPV-BHG712 delivered i.p. was sufficient to
block EphB4 phosphorylation in the rat lungs. (c) The compound
successfully blocked glomerular EphB4 forward signaling at
day (D) 9 of nephritis without any influence on pSrc and
phosphorylated extracellular signal-regulated (pERK) levels.
(d) EphB2 was not detected in the nephritic glomeruli (original
magnification  600). (e) EphA2 was expressed but not
phosphorylated in the healthy and nephritic glomeruli (n¼ 3 in
control (ctrl), n¼ 4 D9/vehicle (veh) and D9/BHG712; each n is a
glomerular lysate from one animal). Negative (Neg) ctrl: MiaPaCa2
human pancreatic carcinoma cells stimulated with immunoglobulin
(Ig)G; positive (Pos) ctrl: cells stimulated with ephrinA1/Fc for
40min. n¼ 3 in d; d and e are representative results. Concentration
of IgG and ephrinA1/Fc in e: 1 mg/ml. IP, immunoprecipitation;
PTyr, phosphotyrosine; WB, western blotting.
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(Figure 4f), although overall macrophage number per section
was still low compared to the total glomerular cellularity.
To gain a more global view of the molecular mechanisms
of glomerular repair, we next focussed on other growth
factors known to have an important role in glomeruli. We
examined whether NPV-BHG712 treatment influences the
expression of Tie-2 receptor relevant for capillary recovery
from Thy1.1 nephritis,19 platelet-derived growth factor
receptor b important for mesangial normalization during
nephritis,20 and podocyte vascular endothelial growth factor
(VEGF) maintaining VEGFR2-expressing endothelium.21
Tie-2 receptor expression increased during nephritis and
these changes were not influenced by EphB4 inhibition.
Platelet-derived growth factor receptor b was also upregulated
in nephritic rats; this increase was even more pronounced
following NPV-BHG712 treatment (Figure 4g). VEGF was
expressed by podocytes located at the glomerular periphery
in nephritic animals; after NPV-BHG712 treatment, only single
podocytes expressed this growth factor (Figure 4h, arrow).
Inhibition of EphB4 signaling during nephritis leads to
podocyte injury
Next, we evaluated podocyte morphology with different
microscopy techniques. Podocytes of vehicle-treated nephri-
tic rats were conspicuous cells with well-developed cell bodies
(Figure 5a, d, and g); podocytes of NPV-BHG712-treated
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Figure 3 |NPV-BHG712 application to healthy rats does not affect kidney function or glomerular morphology. (a) NPV-BHG712 or
vehicle was administered to healthy rats for 4 or 16 days (D). (b) NPV- BHG712 caused neither podocyte loss nor any morphological changes
of foot processes (arrows) or (d, e) endothelial fenestrations (arrowheads) as compared to the (c) vehicle. (f, g) The gross glomerular
morphology was intact in both groups. NPV-BHG712 applied to healthy rats did not induce (h) a smooth muscle actin expression by
mesangial cells or (i) cause any disturbance in the appearance of the CD31-positive endothelial area. Original magnification: (f–i)  600.
Panels c–e are transmission electron micrograph pictures; f–g are periodic acid–Schiff-stained sections. ctrl, control; PBS, phosphate-buffered
saline; NS, not significant. *P40.05.
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Figure 4 |Histomorphological aspects of kidney recovery from Thy1.1 nephritis after NPV-BHG712 administration. (a) NPV-BHG712
or vehicle was administered to nephritic rats according to the schedule. (b, c) Thy1.1 nephritis is characterized by increased kidney/body
weight ratio and albuminuria, NPV-BHG712 administration from days (D) 5–9 did not influence any of these features. (d) The compound
aggravated the injury of glomerular capillaries as assessed by the presence of glomeruli with microaneurysms, led to the (e) increase
of glomerular volume and (f) reduced the number of glomerular ED1-positive macrophages. (g) Glomerular Tie-2 was slightly upregulated
during nephritis independently of EphB4 inhibition. Platelet-derived growth factor receptor b (PDGFRb) was upregulated during nephritis;
this upregulation increased markedly after NPV-BHG712 treatment. (h) Only single podocytes (arrow) expressed vascular endothelial growth
factor (VEGF) as a result of compound application. Quantification of the number of VEGF-expressing podocytes per total number of
podocytes on the glomerular section confirmed VEGF downregulation. ctrl, control; NS, not significant. *Po0.05; **Po0.01; ***Po0.001.
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nephritic animals showed evidence of injury including pseudo-
cyst formation (Figure 5b and c, asterisks). Semithin sections
confirmed the presence of multiple podocyte pseudocysts in
this group (Figure 5e and f, asterisks). Some of the capillary
loops were also enlarged (Figure 5f, star). Transmission elec-
tron microscopy revealed that gross podocyte morphology
(Figure 5g), their foot processes (Figure 5j, arrow), and
endothelial fenestrations (Figure 5j, arrowhead) were relatively
intact in nephritic rats treated with vehicle. In contrast,
podocytes of NPV-BHG712-treated rats presented several
morphological defects including vacuolization and microvillous
transformation (Figure 5h, thin arrows), fusion of foot processes
(Figure 5h, k, and l, arrows), and absorption droplets (Figure
5k, thin arrows). Apical membranes of podocytes often
showed extensive shedding into the Bowman space (Figure 5f
and l, thin arrows). Also, the endothelium showed abnormal
architecture in these animals: focal loss of fenestrations
(Figure 5h, k, and l, arrowheads), patchy widening of the
subendothelial space, and even occlusion of capillary lumen,
probably due to the expanding mesangium (Figure 5h, i, k,
and l, stars). Enlarged and hypocellular mesangial regions
with strikingly expanded matrix were significantly more often
seen after NPV-BHG712 (Figure 5n, star) as compared to
the compact mesangial regions in the vehicle-treated rats
(Figure 5m), which are typical for nephritis. Quantification of
podocyte number per glomerulus revealed that 4 days of
NPV-BHG712 administration to nephritic animals led to a
podocyte loss of around 20% (Figure 5o). TUNEL-positive
podocytes were present in both vehicle and NPV-BHG712-
treated nephritic groups; their number was significantly higher
in nephritic rats receiving NPV-BHG712 (Figure 5p and q).
Prolonged NPV-BHG712 administration to nephritic rats
increases albuminuria and impairs mesangial recovery
As we did not see any effect of EphB4 inhibition on albuminuria
despite significant morphological changes, NPV-BHG712 or
vehicle was administered to nephritic rats for a longer period
of time (between days 5 and 21, Figure 6a). We still observed
a podocyte loss of about 20%, but now albuminuria increased
significantly in NPV-BHG712-treated animals (Figure 6b and
c), with no changes in the glomerulosclerosis area (Figure 6d).
At day 21 of nephritis, the aSMA-positive mesangial region
was already largely resolved and capillary loops were clearly
visible throughout the glomerular area in the vehicle-treated
rats (Figure 6e and f). When nephritic rats were treated with
NPV-BHG712, an enlarged hypocellular mesangial area
(Figure 6i, star) with expanded matrix and aSMA-positive
cells engulfing and surrounding capillary loops (Figure 6h,
arrow and star) was seen. However, the foot processes
of the remaining podocytes were intact in both the vehicle-
(Figure 6g, arrow) and compound-treated groups (Figure 6j,
arrow). In the NPV-BHG712-treated rats, endothelial cells of
the open capillary loops showed only focal thickening (Figure
6j, arrowhead). The quantification of aSMA- and fibronectin-
positive area confirmed their enlargement in NPV-BHG712-
treated rats (Figure 6k and l, respectively), but with less-
proliferating mesangial cells (Figure 6m). To address a potential
toxicity of NPV-BHG712, weight change was monitored daily
and the liver weight was recorded at the end of the experiment.
After 21 days vehicle-treated nephritic rats were 130.5±21.9 g
heavier and the liver was 4.2±0.1% of the total body weight
at the end of the experiment (n¼ 4). At the same time, NPV-
BHG712-treated nephritic rats gained 125.5±17.7 g and their
liver was 4.2±0.3% of the body weight (n¼ 4). Thus, there
were no differences with regard to these parameters between
compound- and vehicle-treated rats.
NPV-BHG712 application to Thy1.1 nephritic rats inhibits
intussusceptive angiogenic repair
As we and others have shown that intussusceptive angiogen-
esis is required for glomerular capillary recovery from Thy1.1
nephritis,22,23 we examined the dynamics of this process after
NPV-BHG712 administration to nephritic rats. In contrast
to sprouting angiogenesis, intussusception causes capillary
growth by insertion of tissue pillars inside the vessel lumen.
This process corresponds to ‘tiny holes’ on scanning electron
microscope images,24 which were absent in glomerular casts
of healthy rats (Figure 7a and d). Capillaries of nephritic
vehicle-treated rats presented multiple openings (Figure 7b)
that could be divided into tiny holes and small capillary loops
based on their size (Figure 7e, arrows and arrowheads,
respectively). In contrast, tiny holes and small capillary
loops were only occasionally seen in NPV-BHG712-treated
nephritic animals (Figure 7c and f, arrows and arrowheads).
Additionally, the capillary channels in this group appeared
to be heterogeneous and less dense in some lobules
(Figure 7c and f). Morphometrical analysis revealed that
NPV-BHG712 administration to nephritic rats reduced the
density of pillars and small capillary loops as compared to
vehicle-treated animals (Figure 7g and h). Glomerular
endothelial cells, a cell type critical for pillar formation,24
were seen throughout the entire glomerular surface in healthy
rats, whereas at day 9 CD31-positive cells were positioned at
the periphery of glomerular lobules. In the NPV-BHG712-
treated nephritic group, glomerular capillaries were less
dense, i.e., CD31 immunoreactivity was often absent at the
periphery of the lobules (Figure 7i, arrows) and the area
occupied by CD31-positive capillary loops was significantly
diminished (Figure 7j).
EphB4 forward signaling partially reverses transforming
growth factor (TGF)b1-induced podocyte apoptosis in vitro
In view of these findings we hypothesized that podocyte
EphB4 forward signaling could rescue podocytes from other
types of injury, and performed in vitro studies with a well-
characterized, immortalized podocyte cell line.25 Differentiated
and undifferentiated podocytes express EphB4 receptor and
ephrinBs (Figure 8a). EphB4 was not phosphorylated in
differentiated podocytes, but was activated by exogenous
ephrinB2/Fc (Figure 8b). EphB4 and ephrinB2 colocalized at
the plasma membrane, but EphB4 was also located in
cytoplasmic clusters (Figure 8c). Phosphorylated ephrinBs
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were expressed at the plasma membrane (Figure 8d, arrow)
and additionally colocalized with phalloidin at the end of stress
fibers consistent with expression in focal adhesions (Figure 6d,
magnified picture). As we had found increased podocyte
apoptosis in nephritic rats treated with NPV-BHG712 (Figure
5p and q), we looked for an in vitro correlate of this effect.
Serum starvation induced the presence of the apoptosis
marker poly (ADP-ribose) polymerase fragment26 and this
effect was potentiated by TGFb1,27 a cytokine reported to
be released during Thy1.1 nephritis by activated mesangial
cells.28 Coincubation of TGFb1 with ephrinB2/Fc reduced
the abundance of the poly (ADP-ribose) polymerase
fragment. However, the addition of NPV-BHG712 blocked the
protective effects of ephrinB2/Fc on TGFb1-mediated apoptosis
(Figure 8e).
DISCUSSION
EphB4 activation in podocytes during Thy1.1 nephritis is a
protective mechanism against injury
During Thy1.1 nephritis, podocytes, in contrast to mesan-
gium and endothelium, do not present much morphological
evidence of injury. However, it has already been suggested
that podocytes help to preserve the glomerular architecture
until proliferation and regeneration of the mesangial cells.29
Podocytes thus seem to have a key role during the early phase
of injury; however, little is known about the mechanisms
allowing them to react to the transient capillary collapse. We
present evidence that activation of EphB4 forward signaling
is one of these mechanisms.
In our model, podocyte injury and loss was not accom-
panied by aggravation of the albuminuria when rats were
treated with the compound for a short period of time. However,
NPV-BHG712 administration over 16 days significantly
increased albuminuria while the podocyte loss remained
stable at about 20%. At this time point (day 21 of nephritis)
the remaining podocytes displayed a normal morphology but
the mesangial reaction was clearly disturbed, with large hypo-
cellular areas accompanied by matrix expansion. In our model,
thus, the matrix production and cell activation does not
correspond to the overall mesangial cellularity. One explana-
tion would be that the aSMA-positive area is increased together
with the decrease in cell number due to the mesangial
hypertrophy. The mesangial phenotype we observed is quite
reminiscent of the mesangial cell growth during the diabetic
state where a transient phase of mesangial proliferation is
followed by growth arrest, hypertrophy, and an increase in
synthesis of the extracellular matrix.30 Interestingly, it has
also been shown that mesangial proliferation can be dis-
sociated from mesangial cell migration.31
These findings strongly suggest that an intact podocyte
EphB4 signaling is required for mesangial normalization after
acute Thy1.1 nephritis. The increased number of microaneurysms
at day 9 of nephritis could also be explained by the observed
reduced mesangial cellularity consistent with mesangiolysis.
Within the glomerulus, the importance of paracrine
signaling has already been well established between podocytes
secreting VEGF and the VEGFR2-expressing endothelium.21
Interestingly, a case report of a patient treated with anti-
VEGF antibody in combination with interferon a2b showed a
strikingly similar glomerular phenotype to our rats: mesan-
gial interposition, subendothelial electron-lucent deposits,
mesangial hypocellularity, but relatively intact foot processes
and mild proteinuria.32 Furthermore, Das et al.33 reported
recently that in hepatic stellate cells VEGF production is
controlled by EphB4. Our results suggest that a similar
mechanism operates in nephritic podocytes.
What triggers podocyte EphB4 signaling during Thy1.1
nephritis?
Our findings raise an important issue as to which stimuli
could trigger EphB4 signaling during acute Thy1.1 nephritis.
One explanation would be that EphB4 receptor signals in
response to mechanical stress caused by podocyte stretching
due to the capillary enlargement, as it has been shown that
podocytes respond to this kind of challenge.34,35 In the NPV-
BHG712-treated nephritic group, glomerular volume was
increased together with a reduced podocyte number; during
that period, however, we could never observe denuded basement
membranes. It is therefore conceivable that podocytes are
stretched to take over the function of lost cells. Furthermore,
the endothelial expression of Eph receptors and ephrins
is regulated by altered shear stress.36,37 A second question
addresses the role of ephrinBs in activating the receptor.
EphB4 and ephrinBs are expressed at different podocyte
Figure 5 | Inhibition of EphB4 signaling during nephritis leads to podocyte injury. (a, d, g) Podocytes of nephritic-vehicle treated rats
are normal, whereas podocytes of NPV-BHG712-treated nephritic animals presented classical evidence of injury, such as (b, c, e, f)
pseudocysts (asterisks) and (k) absorption droplets (thin arrows). (f) Some capillaries in the NPV-BHG712-treated group were enlarged (star).
(h) Podocytes of NPV-BHG712-treated rats showed vacuolization and microvillous transformation (thin arrows) and (h, k, l) fusion of foot
processes into one layer (arrows). (h, k, l) Endothelial cells in the NVP-BHG712-treated group lost fenestrations (arrowheads) and (h, i, k, l)
their subendothelial space was thicker (stars). (j) Foot processes and endothelial fenestrations were intact in nephritic vehicle-treated rats
(arrow and arrowhead, respectively). (n) Mesangial regions of some glomerular lobules of BHG712-treated animals were hypocellular (star)
and showed significant matrix expansion when compared to (m) vehicle-treated rats. (o) There was no difference in podocyte number
between healthy and nephritic vehicle-treated animals at day (D) 9 of nephritis, but NPV-BHG712 administration to nephritic rats led to a
podocyte loss of around 20%. (p, q) TUNEL-positive podocytes (arrows) and mesangial cells (arrowhead) were detected in NPV-BHG712- and
(q) vehicle-treated nephritic rats (original magnification  1000), but the number of TUNEL-positive podocytes was higher in (p) animals
treated with compound. a–c are scanning electron micrographs of kidneys dried at critical point, d–f represent semithin sections
stained with toluidine blue (original magnification  1000), g–l are transmission electron micrograph pictures, m–n are periodic
acid–Schiff-stained sections (original magnification  600). C, capillary lumen; NS, not significant. *Po0.05; **Po0.01.
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membrane compartments, so how they could interact directly?
One possibility would be that EphB4 expressed at the apical
part would come into contact with ephrinBs located at the
foot processes of detached podocytes ‘swimming’ in the urinary
space. Another potential mechanism to explore would be a
cross-talk between EphB4 and other RTKs as Eph receptors
are quite promiscuous molecules in other cell systems.38–42
The extensive dissection of signaling cross-talks between
EphB4 and other RTKs in podocytes are beyond the scope of
this work and will be the topic of another project.
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EphB4 activation regulates intussusceptive angiogenesis
during capillary repair
Intussusceptive angiogenesis, an alternative to the sprouting
mode of angiogenesis, is a major mechanism permitting the
expansion of the primary capillary plexus and angioadapta-
tion.43 We and others have identified intussusception as the
main angiogenic mode leading to restitution of the glome-
rular capillary structure and filtration surface in Thy1.1
nephritis.22,23 Intussusception starts when endothelial cells
invade the vessel lumen and form a transluminal pillar, which
D0
*
D5 D9 D21
Legend:
Induction of acute Thy1.1 nephritis
D21/vehicle
D21/BHG712
Urine collection
BHG712/vehicle administration
240
220
200
180
Po
do
cy
te
/g
lo
m
er
u
lu
s
R
el
at
ive
 
gl
om
er
u
lo
sc
le
ro
si
s 
ar
ea
Al
bu
m
in
u
ria
 (m
g/2
4h
)
160
Ctr
l
D2
1/v
eh
icle
D2
1/B
HG
71
2
Ctr
l
D9
/ve
hic
le
D2
1/v
eh
icle
D9
/BH
G7
12
D2
1/B
HG
71
2
Ctr
l
D9
/ve
hic
le
D2
1/v
eh
icle
D9
/BH
G7
12
D2
1/B
HG
71
2
Ctr
l
D9
/ve
hic
le
D2
1/v
eh
icle
D9
/BH
G7
12
D2
1/B
HG
71
2
Ctr
l
D2
1/v
eh
icle
D2
1/B
HG
71
2Ctr
l
D2
1/v
eh
icle
D2
1/B
HG
71
2
140
120
αSMA PAS
1.5 μm
1.5 μm
0
2
4
6
NSNS
*
*
8
0.0
0.2
R
el
at
ive
 α
SM
A+
 a
re
a 
pe
r
gl
om
er
u
la
r s
ec
tio
n
R
el
at
ive
 F
N
+ 
ar
ea
 p
er
gl
om
er
u
la
r s
ec
tio
n
PC
NA
+/
α
SM
A+
 c
el
ls 
pe
r
gl
om
er
u
la
r s
ec
tio
n
0.4
0.6
0.8
2.0
1.5
1.0
0.5
0.0 0
1
2
3
2.5
*
*
*
NS
**
0
50
100
150
*
*
Animal killed
D21/vehicle
D21/BHG712
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is further stabilized by mesangial cells.44 Podocytes are regarded
as pericyte-like cells of glomerular capillaries;45,46 therefore
they could contribute to pillar formation and/or stabilization.
As (i) EphB4 is expressed only in glomerular podocytes and
(ii) EphB4 blocking leads to downregulation of the intus-
susceptive response, a previously unrecognized role of podocytes
in regulating intussusceptive angiogenesis is conceivable.
A possible scenario is that EphB4 signaling enables the
foot processes to exert mechanical forces on endothelial cells
via rearrangement of the cytoskeleton. EphB4 could also
regulate the secretion of molecules influencing the pillar-
forming endothelium. Indeed, preliminary results from our
laboratory suggest that podocytes secrete VEGF in response
to EphB4 activation by its cognate ligand ephrinB2/Fc.
However, EphB4 is not the sole regulator of glomerular
intussusception as pillars already form at day 5 of nephritis,23
a time point at which EphB4 is not yet phosphorylated.
In aggregate, our results demonstrate that EphB4 signaling
initiated during Thy1.1 nephritis is an important mechanism
allowing podocytes to adapt to a potentially deleterious event
and thus survive. Given the very limited possibility of podocyte
repopulation, our findings are important to identify path-
ways maintaining their homeostasis upon injury and, in a
broader sense, shed further light on the versatile roles of the
Eph/ephrin system in the adult organism.
MATERIALS AND METHODS
Primary antibodies
The detailed list of primary antibodies is shown in Supplementary
Figure S4 online. Anti-podocin antibody was a kind gift from
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with ephrinB2/Fc 1 mg/ml after 15min. (c) EphB4 is expressed in cytoplasmic clusters and additionally at the plasma membrane, where it
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Prof. P Mundel (Department of Medicine, University of Miami,
Miami, FL).
Animal experimentation
All procedures were conducted according to the NIH guidelines for
the care and use of laboratory animals and with the approval of the
local Animal Ethics Committee. Male Wistar rats (170–190 g) were
obtained from Charles River Laboratories, Sulzfeld, Germany. Acute
Thy1.1 glomerulonephritis was induced by a single intravenous
injection of 1mg/kg b.w. of monoclonal OX7 antibody.47 Rats were
killed on days 5, 9, 14, and 21. Animals receiving the same volume of
saline served as controls. NPV-BHG712 experiments: the compound
was administered daily (time indicated on each graph in Figures 3,
4, and 6), i.p., at the dose of 50mg/kg b.w. Control animals received
the same volume of vehicle (PEG300).
Urinalysis
The high-performance liquid chromatography technique with silica-
based standard size exclusion column (Waters, Milford, MA) was
used to quantify the urinary albumin excretion in urine specimens
collected for 24 h.
Glomeruli isolation, western blotting and
immunoprecipitation
Glomeruli were then isolated using the standard sieving method and
homogenized in lysis buffer.23 Isolated proteins were incubated with
the precipitating antibody overnight at 4 1C, then with Protein A/G
Plus—Agarose beads for 2 h at 4 1C. Pulled proteins were resolved
on SDS-PAGE. When indicated, membranes were stripped with
0.1mol/l glycine pH 2.5 and reprobed with the appropriate antibody
to confirm the efficiency of immunoprecipitation, or with b-actin to
confirm equal lane loading.
Light and electron microscopy; staining protocols
Semithin sections, tissues dried at critical point, and transmission
electron micrograph sections were prepared as previously
described.23
The classical ABC method on formalin-fixed paraffin-embedded
tissue was employed to detect proteins with immunohistochemistry.
Colocalization studies were performed by indirect immunofluores-
cence staining on cryosections and evaluated with laser scanning
microscopy (LSM510; Carl Zeiss, Heidelberg, Germany). TUNEL
staining was performed with the In Situ Cell Death Detection Kit
according to the manufacturer’s instructions (Roche Diagnostics,
Basel, Switzerland). TUNELþ podocytes and mesangial cells were
recognized based on their glomerular location and morphology.
In situ hybridization
In situ hybridization for EphB4 mRNA was performed on formalin-
fixed frozen sections with the probe validated in Erber et al.14 The
probe was labelled with digoxygenin (in situ RNA labelling kit;
Roche Diagnostics) recognized by anti-digoxygenin antibody coupled
with alkaline phosphatise (Roche Diagnostics). The reaction was
developed with BM Purple AP substrate, precipitating (Roche
Diagnostics).
Vascular casting and intussusception quantification
Vascular casts and intussusception quantification were performed
as previously described.23 Tiny hole/small capillary loop
appearance was expressed as numerical density per vessel area.
The vessel area was estimated with iTEM software (Olympus,
Hamburg, Germany) using the grid method: a grid was placed on
each photograph included in the quantification and the number of
grid intersections hitting a capillary was quantified. As numerical
density per vessel area is the ratio between the number of tiny holes/
small capillary loops and the relative vessel area, it has no unit.
Morphometry
Glomeruli volume, VG, was quantified from scanning electron
microscope pictures of vascular casts as described previously.23
Macrophages were recognized on formalin-fixed paraffin-embedded
kidney section as ED1-positive cells, and counting of glomeruli with
microaneurysms was performed on formalin-fixed paraffin-embedded
kidney section stained with hematoxylin and eosin. Quantification
of podocyte number per glomerulus was performed as described
previously,48 but podocytes were recognized on formalin-fixed
paraffin-embedded kidney section as synaptopodin-expressing cells
and only podocytes with nucleus (hematoxylin) on the cross section
were counted.
aSMA- and fibronectin-positive area per glomerulus and glome-
rulosclerosis were quantified with ImageJ software (NIH, Bethesda,
MA), the relative glomerulosclerosis area was obtained by dividing
the sclerotic area by the area of the whole glomerular tuft (no units).
The VEGF downregulation following NPV-BHG712 administration
was quantified by counting the VEGF-expressing podocytes and
dividing this number by the podocyte total count in the glomerulus.
The relative CD31-positive area per glomerular section was
quantified with the grid method (ImageJ software). The grid was
placed on each glomerular picture stained with CD31 (original
magnification  600) and the number of grid intersections hitting a
capillary loop was counted.
At least 30 glomeruli were examined for each morphometrical
analysis.
Statistical analysis
All data are expressed as mean±s.d. Statistical analysis was
performed with GraphPad Prism Software (GraphPad Software,
La Jolla, CA). One-way ANOVA with Bonferroni post-hoc test was
used to compare selected pairs of columns. When a scattered plot
type of graph is shown, each point represents one animal. When a
column bar graph is used, the number of animals is specified in the
legends.
Cell culture and in vitro experiments
An immortalized mouse podocyte cell line was obtained from Dr
Andreas Jehle (Department of Biomedicine, University Hospital
Basel, Basel, Switzerland) and cultivated as described previously.25
For immunostaining, cells were fixed with 2% PFA, 4% sucrose
in PBS, and permeabilized with 0.3% Triton-X. Fluorochrome-
conjugated phalloidin was obtained from Invitrogen (Karlsruhe,
Germany).
Podocytes were incubated with TGFb1 (Invitrogen; 10 nmol/l)
and ephrinB2/Fc (1 mg/ml; R&D Systems) in serum-free media.
When indicated, cells were incubated with 50 nmol/l BHG712
diluted in DMSO. After 48 h, cells were collected in lysis buffer and
proteins were isolated for western blotting.
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